Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 2/2015

01-02-2015 | Research Article

Impact of initial FDG PET/CT in the management plan of patients with locally advanced head and neck cancer

Authors: F. Arias, V. Chicata, M. J. García-Velloso, G. Asín, M. Uzcanga, C. Eito, I. Quilez, A. Viudez, J. Saenz, I. Hernández, C. Caicedo, M. Errasti, M. Barrado, F. García-Bragado

Published in: Clinical and Translational Oncology | Issue 2/2015

Login to get access

Abstract

Objective

To determine the impact of initial FDG PET/CT staging on clinical stage and the management plan in patients with locally advanced head and neck cancer (LAHNC).

Materials and methods

We retrospectively reviewed the records of 72 consecutive patients (2007–2010) staged with PET/CT and conventional CT with tumours of hypopharynx/larynx (26 patients, 36 %), oral cavity (17 patients, 24 %), oropharynx (16 patients, 22 %), nasopharynx (12 patients, 17 %), and others (2 %). The impact of PET/CT on management plans was considered high when PET/CT changed the planned treatment modality or treatment intent, and intramodality changes were considered as minor changes with low impact.

Results

FDG PET/CT changed the stage in 27 patients and had high impact on the management plan in 12 % of patients (detection of distant metastases in 6 patients and stage II in 2 patients). Intramodality changes were more frequent: FDG PET/CT altered the TNM stage in 18/72 (25 %) of patients, upstaging N stage in 90 % of patients with low impact.

Conclusions

Initial FDG PET/CT staging not only improves stage but also affects the management plan in LAHNC patients.
Literature
1.
Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer. 2010;46:765–81.PubMedCrossRef
2.
Carvalho AL, Nishimoto IN, Califano JA, Kowalsky LP. Trends in incidence and prognosis for head and neck cancer in the United States: a site-specific analysis of the SEER database. Int J Cancer. 2005;114:806–16.PubMedCrossRef
3.
Porceddu SV, Burmeister BH, Hicks RJ. Role of functional imaging in head and neck squamous cell carcinoma: fluorodeoxyglucose positron emission tomography and beyond. Hematol Oncol Clin North Am. 2008;22:1221–38.PubMedCrossRef
4.
Schöder H, Yeung HW. Positron emission imaging of head and neck cancer, including thyroid carcinoma. Semin Nucl Med. 2004;34:180–97.PubMedCrossRef
5.
Scott AM, Gunawardana DH, Bartholomeusz D, Ramshaw JE, Lin P. PET changes management and improves prognostic stratification in patients with head and neck cancer: results of a multicenter prospective study. J Nucl Med. 2008;49:1593–600.PubMedCrossRef
6.
Yao M, Smith RB, Graham MM, Hoffman HT, Tan H, Funk GF, et al. The role of FDG PET in management of neck metastasis from head-and-neck cancer after definitive radiation treatment. Int J Radiat Oncol Biol Phys. 2005;63:991–9.PubMedCrossRef
7.
Porceddu SV, Jarmolowski E, Hicks RJ, Ware R, Weih L, Rischin D, et al. Utility of positron emission tomography for the detection of disease in residual neck nodes after (chemo) radiotherapy in head and neck cancer. Head Neck. 2005;27:175–81.PubMedCrossRef
8.
Ryan WR, Fee WE Jr, Le QT, Pinto HA. Positron-emission tomography for surveillance of head and neck cancer. Laryngoscope. 2005;115:645–50.PubMedCrossRef
9.
Wong RJ, Lin DT, Schöder H, Patel SG, Gonen M, Wolden S, et al. Diagnostic and prognostic value of [(18)F] fluorodeoxyglucose positron emission tomography for recurrent head and neck squamous cell carcinoma. J Clin Oncol. 2002;20:4199–208.PubMedCrossRef
10.
Andrade RS, Heron DE, Degirmenci B, Filho PA, Branstetter BF, Seethala RR, et al. Posttreatment assessment of response using FDG-PET/CT for patients treated with definitive radiation therapy for head and neck cancers. Int J Radiat Oncol Biol Phys. 2006;65:1315–22.PubMedCrossRef
11.
American joint committee on cancer—cancer staging manual. 7th ed. New York: Springer; 2010.
12.
Kolarova I, Vanasek J, Kandrnal V, Odrazka K, Dusek L, Chrobok V, et al. PET/CT significance for planning radiotherapy of head and neck cancer. Neoplasma. 2012;59(5):536–40.PubMedCrossRef
13.
Newbold K, Powell C. PET/CT in radiotherapy planning for head and neck cancer. Front Oncol. 2012;2:article 189.CrossRef
14.
15.
Suzuki M, Suzuki T, Asai M, Ichimura K, Nibu K, Sugasawa M, et al. Clinicopathologic factors related to cervical lymph node metastasis in a patient with carcinoma of the oral floor. Acta Oto Laryngol. 2007;127:129–35.CrossRef
16.
Wallwork BD, Anderson SR, Coman WB. Squamous cell carcinoma of the floor of the mouth: tumor thickness and the rate of cervical metastasis. ANZ J Surg. 2007;77:761–4.PubMedCrossRef
17.
Sessions DG, Spector GJ, Lenox J, Chao C, Chaudry OA. Analysis of treatment results for oral tongue cancer. Laryngoscope. 2002;112:616–25.PubMedCrossRef
18.
Ahn PH, Garg MK. Positron emission tomography/computed tomography for target delineation in head and neck cancers. Semin Nucl Med. 2008;38:141–8.PubMedCrossRef
19.
Koshy M, Paulino AC, Howell R, Schuster D, Halkar R, Davis LW. F-18 FDG PET–CT fusion in radiotherapy treatment planning for head and neck cancer. Head Neck. 2005;27(6):494–502.PubMedCrossRef
20.
Takeuchi S, Khiewvan B, Fox PS, Swisher SG, Rohren EM, Bassett RL Jr, et al. Impact of initial PET/CT staging in terms of clinical stage, management plan, and prognosis in 592 patients with non-small-cell lung cancer. Eur J Nucl Med Mol Imaging. 2014;41(5):906–14.
21.
Agarwal M, Brahmanday G, Bajaj SK, Ravikrishnan KP, Wong CY. Revisiting the prognostic value of preoperative (18)F-fluoro-2-deoxyglucose ((18)F-FDG) positron emission tomography (PET) in early-stage (I & II) non-small cell lung cancers (NSCLC). Eur J Nucl Med Mol Imaging. 2010;37(4):691–8.
Metadata
Title
Impact of initial FDG PET/CT in the management plan of patients with locally advanced head and neck cancer
Authors
F. Arias
V. Chicata
M. J. García-Velloso
G. Asín
M. Uzcanga
C. Eito
I. Quilez
A. Viudez
J. Saenz
I. Hernández
C. Caicedo
M. Errasti
M. Barrado
F. García-Bragado
Publication date
01-02-2015
Publisher
Springer Milan
Published in
Clinical and Translational Oncology / Issue 2/2015
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-014-1204-8

Other articles of this Issue 2/2015

Clinical and Translational Oncology 2/2015 Go to the issue

Research Article

Two death pathways induced by sorafenib in myeloma cells: Puma-mediated apoptosis and necroptosis

Educational series – Red Series

Biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

Research Article

SMAD4 and TS expression might predict the risk of recurrence after resection of colorectal liver metastases

Brief Research Article

Implementation and assessment of a fast-track programme to improve communication between primary and specialized care in patients with suspected cancer: how to shorten time between initial symptoms of cancer, diagnosis and initiation of treatment

Editorial

Change of the editorial board

Research Article

Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits